Considering the previously demonstrated ability of SYK inhibitors to potentiate the inhibitory activity of FLT3 inhibitors against oncogenic FLT3‐positive leukaemia, we hypothesized that the combination of FLT3 and SYK inhibition might be similarly more effective against cells engineered to co‐express mutant CBL and wt FLT3, as compared to FLT3 inhibition alone. Here, CBL is linked to leukemia.